Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial.
Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial.
复制标题
亚麻籽衍生的木质蛋白补充剂在2型糖尿病患者中的影响：一项随机，双盲，交叉试验。
DOI：
10.1371/journal.pone.0001148
复制
发表时间：
2007-11-07
期刊：
影响因子：
3.7
通讯作者：
Lin, Xu
中科院分区：
文献类型：
--
作者：
Pan, An;Sun, Jianqin;Chen, Yanqiu;Ye, Xingwang;Li, Huaixing;Yu, Zhijie;Wang, Yanfang;Gu, Wenjia;Zhang, Xinyi;Chen, Xiafei;Demark-Wahnefried, Wendy;Liu, Yong;Lin, Xu
亚麻籽消费已被证明可以改善人类的血脂，亚麻籽衍生的木酚素已被证明可以增强动物的血糖控制。该研究旨在研究亚麻籽衍生木脂素补充剂对2型糖尿病患者血糖控制、血脂和胰岛素敏感性的影响。这是一项随机、双盲、安慰剂对照、交叉试验，于2006年4月至12月在中国上海进行。73例伴有轻度高胆固醇血症的2型糖尿病患者入组研究。患者随机接受亚麻籽衍生的木酚素胶囊（每天360 mg木酚素）或安慰剂补充12周，间隔8周的洗脱期。检测HbA 1c、血脂、胰岛素抵抗指数和炎症因子。68人完成了研究并被纳入分析。与安慰剂相比，木脂素补充剂显著改善了通过HbA 1c测量的血糖控制（-0.10 ~0.65% vs. 0.09± 0.52%，P =0.001）;然而，在空腹血糖和胰岛素浓度、胰岛素抵抗和血脂谱中未观察到显著变化。 与基线相比，木酚素补充干预后木酚素代谢物（肠二醇和肠内酯）的尿排泄量显著增加（14.2±18.1 vs. 1.2±2.4 µg/mL，P<0.001）。数据还表明，最小的竞争木酚素和异黄酮的生物利用度时，测量的排泄浓度。每日补充木脂素可使2型糖尿病患者的血糖控制得到适度但具有统计学意义的改善，而不明显影响空腹血糖、血脂和胰岛素敏感性。需要进一步的研究来验证这些发现，并探讨木脂素对2型糖尿病的疗效。ClinicalTrials.gov NCT00363233
Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10±0.65 % vs. 0.09±0.52 %, P = 0.001) compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2±18.1 vs. 1.2±2.4 µg/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes. ClinicalTrials.gov NCT00363233
登录
查看更多内容
影响因子：
158.5
作者：
ANDERSON, JW;JOHNSTONE, BM;COOKNEWELL, ME
通讯作者：
COOKNEWELL, ME
影响因子：
4.5
作者：
Arjmandi, BH;Khan, DA;Derman, R
通讯作者：
Derman, R
影响因子：
7.2
作者：
Lemay, A;Dodin, S;Forest, JC
通讯作者：
Forest, JC
DOI：
10.1016/j.jchromb.2003.09.018
发表时间：
2003-12-05
影响因子：
3
作者：
Nurmi, T;Voutilainen, S;Salonen, JT
通讯作者：
Salonen, JT
影响因子：
16.2
作者：
King, H;Aubert, RE;Herman, WH
通讯作者：
Herman, WH